256,871 Shares in Pfizer Inc. $PFE Acquired by Bcwm LLC

Bcwm LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 256,871 shares of the biopharmaceutical company’s stock, valued at approximately $6,185,000.

Other large investors have also recently added to or reduced their stakes in the company. Berkley W R Corp acquired a new position in shares of Pfizer during the second quarter valued at $23,250,000. Birmingham Capital Management Co. Inc. AL acquired a new stake in shares of Pfizer in the 2nd quarter worth about $2,715,000. Bluefin Capital Management LLC bought a new stake in Pfizer in the 2nd quarter valued at about $459,000. Magnolia Capital Advisors LLC boosted its stake in Pfizer by 4.5% during the 2nd quarter. Magnolia Capital Advisors LLC now owns 16,265 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 705 shares during the period. Finally, Port Capital LLC boosted its stake in Pfizer by 6.6% during the 2nd quarter. Port Capital LLC now owns 9,442 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 583 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.8%

Shares of NYSE:PFE opened at $28.33 on Thursday. The company has a 50 day moving average of $25.44 and a 200-day moving average of $26.29. The firm has a market cap of $161.47 billion, a P/E ratio of 37.28 and a beta of 0.34. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the firm posted $0.78 earnings per share. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PFE shares. Bank of America cut their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Weiss Ratings cut Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. UBS Group reaffirmed a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. BMO Capital Markets reduced their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, HSBC cut Pfizer from a “buy” rating to a “hold” rating and decreased their price target for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.28.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.